The recent integrative bioinformatic analysis of NSCLC samples showed NMU is potentially involved in conferring resistance to alectinib by interacting with five genes previously shown to be involved in conferring drug resistance, i.e., CD80, checkpoint kinase 1 (CHEK1), MYCN proto-oncogene, bHLH transcription factor (MYCN), pim-1 proto-oncogene (PIM1), and interleukin 1 receptor antagonist (IL1RN). The gene discussed is CHEK1; the disease is non-small cell lung carcinoma.